Latest News and Press Releases

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on...

ZUG, Sviss, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) („Oculis” eða „félagið”), tilkynnti í dag niðurstöður aðalfundar 2025, sem haldinn var 13. maí 2026 í...

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on...

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site...

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June...

ZUG, Sviss, May 11, 2026 (GLOBE NEWSWIRE) -- Þróun miðar samkvæmt áætlun með OCS-01 í fararbroddi þar sem mikilvægum áfanga var náð (lok síðustu eftirfylgniheimsóknar) í báðum fasa 3...

ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic...

Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME...

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular...

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...